{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:03:53Z","timestamp":1788206633667,"version":"build-2803163510"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/md.0b013e3182397166","type":"journal-article","created":{"date-parts":[[2011,10,26]],"date-time":"2011-10-26T04:58:03Z","timestamp":1319605083000},"page":"404-411","source":"Crossref","is-referenced-by-count":38,"title":["Acquired von Willebrand Syndrome Associated With Monoclonal Gammopathy"],"prefix":"10.1097","volume":"90","author":[{"given":"Sophie","family":"Voisin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Lefran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Sigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Trossa\u00ebrt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210226","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.intimp.2005.11.013","article-title":"Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.","volume":"6","author":"Bayary","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"R2-6-20210226","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/j.1538-7836.2006.02072.x","article-title":"Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor.","volume":"4","author":"Coleman","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"Suppl 3","key":"R3-6-20210226","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2516.2008.01745.x","article-title":"Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome.","volume":"14","author":"Collins","year":"2008","journal-title":"Haemophilia"},{"key":"R4-6-20210226","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-8411(05)80020-4","article-title":"A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg).","volume":"3","author":"Dietrich","year":"1990","journal-title":"J Autoimmun"},{"key":"R5-6-20210226","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.20760","article-title":"Acquired von Willebrand syndrome: diagnostic problems and therapeutic options.","volume":"82","author":"Eikenboom","year":"2007","journal-title":"Am J Hematol"},{"key":"R6-6-20210226","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1055\/s-2006-947869","article-title":"The utility of the PFA-100 in the identification of von Willebrand disease: a concise review.","volume":"32","author":"Favaloro","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R8-6-20210226","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1538-7836.2008.02917.x","article-title":"Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?","volume":"6","author":"Federici","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R9-6-20210226","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/13543784.9.2.347","article-title":"Therapeutic approaches to acquired von Willebrand syndrome.","volume":"9","author":"Federici","year":"2000","journal-title":"Expert Opin Invest Drug"},{"key":"R10-6-20210226","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.humimm.2005.01.031","article-title":"Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.","volume":"66","author":"Federici","year":"2005","journal-title":"Hum Immunol"},{"key":"R11-6-20210226","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-0037-1619606","article-title":"Acquired von Willebrand syndrome 2004: International Registry-diagnosis and management from online to bedside.","volume":"24","author":"Federici","year":"2004","journal-title":"Hamostaseologie"},{"key":"R12-6-20210226","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"key":"R13-6-20210226","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","article-title":"Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.","volume":"92","author":"Federici","year":"1998","journal-title":"Blood"},{"key":"R14-6-20210226","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood-2008-03-143586","article-title":"Acquired factor VIII inhibitors.","volume":"112","author":"Franchini","year":"2008","journal-title":"Blood"},{"key":"R15-6-20210226","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.20830","article-title":"Acquired von Willebrand syndrome: an update.","volume":"82","author":"Franchini","year":"2007","journal-title":"Am J Hematol"},{"key":"R16-6-20210226","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood.V91.4.1325","article-title":"Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.","volume":"91","author":"Fressinaud","year":"1998","journal-title":"Blood"},{"key":"R17-6-20210226","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood.V66.3.562.562","article-title":"Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody.","volume":"66","author":"Fricke","year":"1985","journal-title":"Blood"},{"key":"R18-6-20210226","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tracli.2007.04.003","article-title":"Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders.","volume":"14","author":"Graff-Dubois","year":"2007","journal-title":"Transfus Clin Biol"},{"key":"R19-6-20210226","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1160\/TH07-07-0456","article-title":"Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome.","volume":"99","author":"Grimaldi","year":"2008","journal-title":"Thromb Haemost"},{"key":"R20-6-20210226","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000057286","article-title":"Low-dosage intravenous immunoglobulin in the management of a patient with acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance.","volume":"32","author":"Hayashi","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"R21-6-20210226","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"R22-6-20210226","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.20829","article-title":"Association of acquired von Willebrand syndrome with AL amyloidosis.","volume":"82","author":"Kos","year":"2007","journal-title":"Am J Hematol"},{"key":"R23-6-20210226","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)62333-1","article-title":"Acquired von Willebrand disease.","volume":"77","author":"Kumar","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"R24-6-20210226","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","article-title":"Monoclonal gammopathy of undetermined significance.","volume":"134","author":"Kyle","year":"2006","journal-title":"Br J Haematol"},{"key":"R25-6-20210226","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2141.2007.06873.x","article-title":"Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.","volume":"139","author":"Kyle","year":"2007","journal-title":"Br J Haematol"},{"key":"R26-6-20210226","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"R27-6-20210226","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"R28-6-20210226","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1055\/s-0037-1615752","article-title":"Pharmacokinetic studies with FVIII\/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome.","volume":"85","author":"Luboshitz","year":"2001","journal-title":"Thromb Haemost"},{"key":"R29-6-20210226","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V64.3.614.614","article-title":"Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.","volume":"64","author":"Mannucci","year":"1984","journal-title":"Blood"},{"key":"R30-6-20210226","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1365-2141.2008.07538.x","article-title":"Is rituximab effective in acquired von Willebrand syndrome?","volume":"144","author":"Mazoyer","year":"2009","journal-title":"Br J Haematol"},{"key":"R31-6-20210226","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-2006-949663","article-title":"Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.","volume":"32","author":"Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"R32-6-20210226","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V91.10.3623","article-title":"Clinical significance of inhibitors in acquired von Willebrand syndrome.","volume":"91","author":"Mohri","year":"1998","journal-title":"Blood"},{"key":"R33-6-20210226","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","article-title":"Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.","volume":"27","author":"Negi","year":"2007","journal-title":"J Clin Immunol"},{"key":"R34-6-20210226","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4065\/81.5.693","article-title":"Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.","volume":"81","author":"Rajkumar","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"R35-6-20210226","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2516.2003.00750.x","article-title":"A new ELISA assay for diagnosis of acquired von Willebrand syndrome.","volume":"9","author":"Siaka","year":"2003","journal-title":"Haemophilia"},{"key":"R36-6-20210226","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2003-11-4075","article-title":"Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia.","volume":"103","author":"Stasi","year":"2004","journal-title":"Blood"},{"key":"R37-6-20210226","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0002-9343(97)00239-8","article-title":"Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment.","volume":"103","author":"Tefferi","year":"1997","journal-title":"Am J Med"},{"key":"R38-6-20210226","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1538-7836.2008.02909.x","article-title":"Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.","volume":"6","author":"Tiede","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R39-6-20210226","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0950-3536(98)80051-6","article-title":"Acquired von Willebrand disease.","volume":"11","author":"van Genderen","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"R40-6-20210226","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000462547","article-title":"Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease.","volume":"67","author":"van Genderen","year":"1994","journal-title":"Vox Sang"},{"key":"R41-6-20210226","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01698487","article-title":"Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.","volume":"69","author":"van Genderen","year":"1994","journal-title":"Ann Hematol"},{"key":"R42-6-20210226","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0038-1653887","article-title":"High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease.","volume":"73","author":"van Genderen","year":"1995","journal-title":"Thromb Haemost"},{"key":"R43-6-20210226","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood.V84.10.3378.3378","article-title":"Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.","volume":"84","author":"van Genderen","year":"1994","journal-title":"Blood"},{"key":"R44-6-20210226","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/MD.0b013e3181e763be","article-title":"Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients.","volume":"89","author":"Varettoni","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"R45-6-20210226","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors.","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0b013e3182397166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:24:14Z","timestamp":1786047854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201111000-00006"}},"subtitle":["A Single-Center Study of 36 Patients"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0b013e3182397166","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}